CompletedEUCTR 2013-005451-32
Effects of F17464 in acute exacerbation of schizophrenia.
This historical record does not confirm current site availability.
Historical research recordMultiple countries
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Hungary · Latvia and 1 more location
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 142
- Sponsor
- Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Hungary, Latvia, Romania
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2013-005451-32
- Official title
Show the full official title
Effects of F17464 in acute exacerbation of schizophrenia.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Hungary · Latvia · Romania
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF), a research institute.
